No Data
Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Popularity With Investors Under Threat As Stock Sinks 28%
Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Is Making Moderate Use Of Debt
Shuangcheng Pharmaceutical: 2024 Annual Performance Forecast of Hainan Shuangcheng Pharmaceutical Co., Ltd.
Review of the A-share consecutive board leaders in 2024: Hainan Shuangcheng Pharmaceuticals and Guangdong Songfa Ceramics both achieved 14 consecutive boards, ranking first. Daqian Ecology & Environment Group and three other stocks followed closely with 1
① The 2024 A-share market has officially closed, with a number of stocks experiencing consecutive gains, among which Hainan Shuangcheng Pharmaceuticals and Guangdong Songfa Ceramics had the most days of consecutive price increases at 14; ② Attached is the ranking of the number of consecutive price increases of A-share listed companies in 2024 (attached table).
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Change of Pharmaceutical Production License.
On December 26, Gu Long Hui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the company recently obtained the revised "Pharmaceutical Production License" issued by the Hainan Provincial Drug Administration. The main change involves the approval for the company to expand its production scope at the production address of 16 Xingguo Road, Xiuying District, Haikou City: Active Pharmaceutical Ingredients (C139, C141), with production lines being: Active Pharmaceutical Ingredient Workshop No. 2 C139 production line, C141 production line, (limited to registered declaration use). Other content remains unchanged.
Some Confidence Is Lacking In Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) As Shares Slide 30%
Here's Why Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Can Afford Some Debt
